1 Department of Surgery, University of Virginia, Charlottesville, VA, USA.
2 School of Medicine, University of Virginia, Charlottesville, VA, USA.
Angiology. 2019 Nov;70(10):947-951. doi: 10.1177/0003319719858784. Epub 2019 Jun 25.
Medical therapy for mycotic aortic aneurysms (MAA) is almost universally fatal, while surgical and endovascular repair carry high morbidity and mortality. The purpose of this study was to compare outcomes between patients receiving treatment for MAA. Records were obtained and patients with MAA were stratified by intervention: endovascular repair, open surgery, and medical therapy. Primary outcomes were aneurysm-related mortality and survival. Risk-adjusted associations with mortality were assessed using time-to-event analysis. Thirty-eight patients were identified (median age, 67). Twenty-one underwent endovascular repair,10 had open surgery and 7 received medical therapy alone. Overall mortality was 47% (n = 18), with 94% aneurysm related. Median survival was significantly longer in the endovascular group (747.0 [161-1249]) vs open surgery and medical therapy (507.5 [34-806] and 66 [13-146] days, respectively; = .02). The endovascular group had significantly fewer perioperative complications (43% vs 80%, < .01). However, 4 endovascular patients experienced reinfection versus no open surgery patients. Mortality risk factors included medical therapy (hazard ratio [HR]: 5.3, < .01) and aneurysm size (HR: 1.4 per 1-cm increase in diameter, = .03). Endovascular repair of MAA was associated with the best long-term survival and lowest perioperative complication rate, although it is associated with greater reinfection. These tradeoffs should be considered when selecting which procedure is best for a patient.
对于真菌性主动脉瘤(MAA)的治疗,内科治疗几乎普遍致命,而手术和血管内修复的发病率和死亡率都很高。本研究的目的是比较接受 MAA 治疗的患者的结局。获取记录,并根据干预措施将 MAA 患者分层:血管内修复、开放性手术和内科治疗。主要结局是与动脉瘤相关的死亡率和生存率。使用生存时间分析评估与死亡率相关的风险调整关联。共确定了 38 名患者(中位年龄 67 岁)。21 例行血管内修复,10 例行开放性手术,7 例单独接受内科治疗。总死亡率为 47%(n=18),94%与动脉瘤相关。血管内组的中位生存期明显长于开放手术和内科治疗组(747.0[161-1249]与 507.5[34-806]和 66[13-146]天, =.02)。血管内组围手术期并发症明显较少(43%比 80%, <.01)。然而,4 例血管内患者发生再感染,而无开放手术患者发生再感染。死亡的危险因素包括内科治疗(风险比[HR]:5.3, <.01)和动脉瘤大小(HR:直径每增加 1cm 增加 1.4, =.03)。尽管 MAA 的血管内修复与更高的再感染相关,但与内科治疗和开放手术相比,它与最佳的长期生存率和最低的围手术期并发症发生率相关。在选择哪种手术对患者最有利时,应考虑这些权衡。